Alector, Inc. (NASDAQ:ALEC) Shares Bought by Massachusetts Financial Services Co. MA

Massachusetts Financial Services Co. MA raised its stake in Alector, Inc. (NASDAQ:ALEC) by 3.5% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 112,920 shares of the company’s stock after acquiring an additional 3,790 shares during the quarter. Massachusetts Financial Services Co. MA owned approximately 0.12% of Alector worth $513,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also made changes to their positions in ALEC. BNP Paribas Financial Markets lifted its stake in shares of Alector by 17.7% in the 4th quarter. BNP Paribas Financial Markets now owns 94,955 shares of the company’s stock valued at $758,000 after purchasing an additional 14,287 shares during the period. Principal Financial Group Inc. grew its position in shares of Alector by 17.5% during the 4th quarter. Principal Financial Group Inc. now owns 48,755 shares of the company’s stock valued at $389,000 after acquiring an additional 7,262 shares during the period. Campbell & CO Investment Adviser LLC acquired a new stake in shares of Alector during the 4th quarter valued at about $1,920,000. Rafferty Asset Management LLC raised its holdings in Alector by 2.3% in the 4th quarter. Rafferty Asset Management LLC now owns 190,911 shares of the company’s stock worth $1,523,000 after purchasing an additional 4,287 shares during the period. Finally, Allspring Global Investments Holdings LLC acquired a new position in Alector in the 1st quarter worth about $40,000. Institutional investors and hedge funds own 85.83% of the company’s stock.

Insider Buying and Selling at Alector

In related news, CEO Arnon Rosenthal sold 26,499 shares of the stock in a transaction that occurred on Tuesday, September 3rd. The stock was sold at an average price of $4.88, for a total value of $129,315.12. Following the completion of the sale, the chief executive officer now owns 1,948,746 shares of the company’s stock, valued at $9,509,880.48. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. In related news, Director Paula Hammond sold 10,500 shares of the firm’s stock in a transaction dated Monday, August 12th. The shares were sold at an average price of $5.06, for a total transaction of $53,130.00. Following the completion of the sale, the director now directly owns 60,209 shares in the company, valued at $304,657.54. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Arnon Rosenthal sold 26,499 shares of the business’s stock in a transaction dated Tuesday, September 3rd. The shares were sold at an average price of $4.88, for a total transaction of $129,315.12. Following the completion of the transaction, the chief executive officer now owns 1,948,746 shares in the company, valued at $9,509,880.48. The disclosure for this sale can be found here. In the last quarter, insiders sold 58,222 shares of company stock worth $286,013. Insiders own 9.10% of the company’s stock.

Analyst Ratings Changes

Several brokerages have recently weighed in on ALEC. HC Wainwright reaffirmed a “buy” rating and set a $35.00 target price on shares of Alector in a research note on Thursday, June 20th. Cantor Fitzgerald reissued an “overweight” rating on shares of Alector in a research note on Tuesday, September 17th. One investment analyst has rated the stock with a sell rating and five have given a buy rating to the company’s stock. According to MarketBeat, Alector has a consensus rating of “Moderate Buy” and an average price target of $15.00.

Alector Price Performance

Shares of NASDAQ:ALEC opened at $5.75 on Monday. The business’s 50 day moving average price is $5.51 and its 200-day moving average price is $5.36. Alector, Inc. has a 1 year low of $3.66 and a 1 year high of $8.90. The firm has a market capitalization of $554.21 million, a PE ratio of -4.17 and a beta of 0.68.

Alector (NASDAQ:ALEC) last issued its earnings results on Wednesday, August 7th. The company reported ($0.40) EPS for the quarter, beating analysts’ consensus estimates of ($0.49) by $0.09. The business had revenue of $15.08 million during the quarter, compared to analysts’ expectations of $16.04 million. Alector had a negative net margin of 290.66% and a negative return on equity of 102.63%. During the same period in the prior year, the business earned $0.02 earnings per share. As a group, analysts expect that Alector, Inc. will post -1.92 earnings per share for the current year.

Alector Company Profile

Alector, Inc, a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases.